Enhanced Osteogenic Differentiation in Zoledronate-Treated Osteoporotic Patients

Bisphosphonates are well known inhibitors of osteoclast activity and thus may be employed to influence osteoblast activity. The present study was designed to evaluate the in vivo effects of zoledronic acid (ZA) on the proliferation and osteoblastic commitment of mesenchymal stem cells (MSC) in osteoporotic patients. We studied 22 postmenopausal osteoporotic patients. Densitometric, biochemical, cellular and molecular data were collected before as well as after 6 and 12 months of ZA treatment. Peripheral blood MSC-like cells were quantified by colony-forming unit fibroblastic assay; their osteogenic differentiation potential was evaluated after 3 and 7 days of induction, respectively. Circulating MSCs showed significantly increased expression levels of osteoblastic marker genes such as Runt-related transcription factor 2 (RUNX2), and Osteonectin (SPARC) during the 12 months of monitoring time. Lumbar bone mineral density (BMD) variation and SPARC gene expression correlated positively. Bone turnover marker levels were significantly lowered after ZA treatment; the effect was more pronounced for C terminal telopeptide (CTX) than for Procollagen Type 1 N-Terminal Propeptide (P1NP) and bone alkaline phosphatase (bALP). Our findings suggest a discrete anabolic activity supported by osteogenic commitment of MSCs, consequent to ZA treatment. We confirm its anabolic effects in vivo on osteogenic precursors.

[1]  J. Alm,et al.  Zoledronic acid in vivo increases in vitro proliferation of rat mesenchymal stromal cells , 2016, Acta orthopaedica.

[2]  L. De Franceschi,et al.  Hypoxia-reperfusion affects osteogenic lineage and promotes sickle cell bone disease. , 2015, Blood.

[3]  M. Pazianas.  Anabolic effects of PTH and the ‘anabolic window’ , 2015, Trends in Endocrinology & Metabolism.

[4]  R. Lindtner,et al.  Osteoanabolic effect of alendronate and zoledronate on bone marrow stromal cells (BMSCs) isolated from aged female osteoporotic patients and its implications for their mode of action in the treatment of age-related bone loss , 2014, Osteoporosis International.

[5]  G. Dorado,et al.  Risedronate positively affects osteogenic differentiation of human mesenchymal stromal cells. , 2013, Archives of medical research.

[6]  B. Al-Nawas,et al.  Zoledronate, ibandronate and clodronate enhance osteoblast differentiation in a dose dependent manner--a quantitative in vitro gene expression analysis of Dlx5, Runx2, OCN, MSX1 and MSX2. , 2011, Journal of cranio-maxillo-facial surgery : official publication of the European Association for Cranio-Maxillo-Facial Surgery.

[7]  R. Eastell,et al.  Bisphosphonates for postmenopausal osteoporosis. , 2011, Bone.

[8]  J. Mönkkönen,et al.  Biochemical and molecular mechanisms of action of bisphosphonates. , 2011, Bone.

[9]  M. Valenti,et al.  Role of Ox-PAPCs in the Differentiation of Mesenchymal Stem Cells (MSCs) and Runx2 and PPARγ2 Expression in MSCs-Like of Osteoporotic Patients , 2011, PloS one.

[10]  S. Giannini,et al.  The effect of risedronate on osteogenic lineage is mediated by cyclooxygenase-2 gene upregulation , 2010, Arthritis research & therapy.

[11]  M. Valenti,et al.  Safety and tolerability of zoledronic acid and other bisphosphonates in osteoporosis management , 2010, Drug, healthcare and patient safety.

[12]  Liza J. Raggatt,et al.  Cellular and Molecular Mechanisms of Bone Remodeling* , 2010, The Journal of Biological Chemistry.

[13]  Wei Li,et al.  Effects of risedronate on bone marrow adipocytes in postmenopausal women , 2009, Osteoporosis International.

[14]  M. Valenti,et al.  Circulating mesenchymal stem cells with abnormal osteogenic differentiation in patients with osteoporosis. , 2009, Arthritis and rheumatism.

[15]  F. Jakob,et al.  Pulse treatment with zoledronic acid causes sustained commitment of bone marrow derived mesenchymal stem cells for osteogenic differentiation. , 2009, Bone.

[16]  M. Valenti,et al.  Gene expression analysis in osteoblastic differentiation from peripheral blood mesenchymal stem cells. , 2008, Bone.

[17]  G. Duque.  Bone and fat connection in aging bone , 2008, Current opinion in rheumatology.

[18]  G. Duque,et al.  Alendronate Has an Anabolic Effect on Bone Through the Differentiation of Mesenchymal Stem Cells , 2007, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[19]  Jacques P. Brown,et al.  Changes to Osteoporosis Prevalence According to Method of Risk Assessment , 2006, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[20]  S. Boonen,et al.  Effect of osteoporosis treatments on risk of non-vertebral fractures: review and meta-analysis of intention-to-treat studies , 2005, Osteoporosis International.

[21]  J. Gimble,et al.  Controlling the balance between osteoblastogenesis and adipogenesis and the consequent therapeutic implications. , 2004, Current opinion in pharmacology.

[22]  Thomas D. Schmittgen,et al.  Real-Time Quantitative PCR , 2002 .

[23]  J. Ingle,et al.  Bisphosphonates directly regulate cell proliferation, differentiation, and gene expression in human osteoblasts. , 2000, Cancer research.

[24]  P. Roberson,et al.  Prevention of osteocyte and osteoblast apoptosis by bisphosphonates and calcitonin. , 1999, The Journal of clinical investigation.

[25]  O. Kozawa,et al.  Tiludronate inhibits interleukin‐6 synthesis in osteoblasts: Inhibition of phospholipase D activation in MC3T3‐E1 cells , 1998, Journal of cellular biochemistry.

[26]  G. Passeri,et al.  Bisphosphonates stimulate formation of osteoblast precursors and mineralized nodules in murine and human bone marrow cultures in vitro and promote early osteoblastogenesis in young and aged mice in vivo. , 1998, Bone.

[27]  G. Golomb,et al.  Structurally different bisphosphonates exert opposing effects on alkaline phosphatase and mineralization in marrow osteoprogenitors , 1998, Journal of cellular biochemistry.

[28]  G. Passeri,et al.  Bisphosphonates inhibit IL-6 production by human osteoblast-like cells. , 1998, Scandinavian journal of rheumatology.

[29]  F. Lecanda,et al.  Regulation of bone matrix protein expression and induction of differentiation of human osteoblasts and human bone marrow stromal cells by bone morphogenetic protein‐2 , 1997, Journal of cellular biochemistry.

[30]  G. Karsenty,et al.  Osf2/Cbfa1: A Transcriptional Activator of Osteoblast Differentiation , 1997, Cell.

[31]  B. Ziegler,et al.  Phenotype analysis of hematopoietic CD34+ cell populations derived from human umbilical cord blood using flow cytometry and cDNA-polymerase chain reaction. , 1994, Blood.

[32]  T. Martin,et al.  Bisphosphonates act on rat bone resorption through the mediation of osteoblasts. , 1993, The Journal of clinical investigation.

[33]  Claus Christiansen,et al.  Diagnosis of Osteoporosis , 1992, Southern medical journal.

[34]  P Meunier,et al.  Osteoporosis and the replacement of cell populations of the marrow by adipose tissue. A quantitative study of 84 iliac bone biopsies. , 1971, Clinical orthopaedics and related research.